Chengdu Hyperway Pharmaceutical Co., Ltd., an innovative drug R&D company founded in January 2019, has completed a Series B+ financing round, with participating investors including Penglai Private Fund, Hengdian Capital, Yufu High‑Quality Industry Mother Fund, Yueyin Medical Fund, and Chengdu Sci‑Tech Innovation Investment Group. The round amount was not disclosed. The capital supports a pipeline of more than 10 differentiated innovative drug programs spanning tumor resistance, tumor immunology, pain, the central nervous system (CNS), autoimmune diseases, and fungal infections — anchored by the company’s distinctive blood‑brain barrier (BBB)-penetrant drug development platform.
Financing Milestone
| Item | Detail |
|---|---|
| Company | Chengdu Hyperway Pharmaceutical Co., Ltd. (founded Jan 2019, Chengdu) |
| Round | Series B+ |
| Announcement Date | 29 Sep 2026 (per financing records) |
| Investors | Penglai Private Fund; Hengdian Capital; Yufu High‑Quality Industry Mother Fund; Yueyin Medical Fund; Chengdu Sci‑Tech Innovation Investment Group |
| Amount | Not disclosed |
| Use of Proceeds | Not disclosed |
| Prior Round | Series B (Oct 2025) – over RMB 200 million (≈ US$28 million) |
Company Profile & Technology Platform
- Focus: A high-growth, high-tech enterprise specializing in innovative drug R&D, oriented to clinical need with innovation as the core driver, targeting first-in-class and best-in-class novel drugs with independent intellectual property.
- Team & Facilities: Nearly 100 full-time employees, with R&D staff exceeding 80%; R&D and office space of more than 2,200 square meters.
- Instrumentation Investment: Tens of millions of RMB invested in advanced precision instruments and equipment.
- Signature Platform: A differentiated brain-penetrant (BBB-crossing) drug development platform — a capability of high strategic value given the historical difficulty of delivering therapeutics into the CNS.
- Pipeline Breadth: 10+ differentiated programs covering tumor resistance, tumor immunology, pain, CNS, autoimmune disease, and fungal infection — areas of pressing medical need.
R&D Progress & Intellectual Property
- Patents: 26 invention patent applications filed, 7 granted within roughly four years of founding.
- Discovery Output: 7 preclinical candidate compounds (PCCs) nominated.
- IND Milestones: 4 IND applications completed, of which 3 have received implicit clinical trial approval and entered Phase I clinical studies.
- International Recognition: Multiple project results selected for international academic conferences, laying a foundation for overseas business expansion.
- Development Philosophy: Addressing patient medication needs across efficacy, safety, and accessibility.
Financing History (per Tianyancha records)
| Date | Round | Amount | Investors |
|---|---|---|---|
| 29 Sep 2026 | Series B+ | Not disclosed | Penglai Private Fund; Hengdian Capital; Yufu High‑Quality Industry Mother Fund; Yueyin Medical Fund; Chengdu Sci‑Tech Investment Group |
| 21 Oct 2025 | Series B | Over RMB 200 million (≈ US$28M) | Huagai Capital; Yuansheng Venture Capital; Daoyuan Capital; Qingsong Capital; Xincheng Fund; Jiatai Xinxing Fund; Haoyue China Medical Industry Fund |
| 21 Apr 2024 | Series A+ | Near RMB 100 million (≈ US$14M) | Xincheng Fund; Ceyuan Capital; Guoyuan Innovation Investment; Shengyuan Zhiping |
| 13 Apr 2021 | Series A | Tens of millions RMB | Huaige Capital; Sichuan Academician Fund |
| 11 Apr 2020 | Angel+ | Tens of millions RMB | Huaige Capital; Chengdu Sci‑Tech Innovation Group |
| 08 May 2019 | Angel | Tens of millions RMB | Xiamen Yiyuan; Chuan Creation Investment |
The progression from angel funding in 2019 to an oversubscribed-style institutional Series B in 2025 and the new B+ round in 2026 reflects sustained investor confidence through multiple market cycles.
Market Context – CNS, BBB Delivery and China Biotech Funding
- BBB as a Frontier: Delivering drugs across the blood‑brain barrier remains one of pharma’s hardest technical challenges; companies with dedicated brain-penetrant platforms are scarce and strategically sought after.
- CNS & Pain Unmet Need: Neurological, psychiatric, and chronic pain indications carry large patient populations with limited effective therapies — a rationale for Hyperway’s CNS and pain programs.
- Beyond Oncology: Coverage of autoimmune disease and fungal infection adds diversification, with invasive fungal infections an area of rising clinical concern in immunocompromised populations.
- China Funding Environment: Private biotech financing in China has concentrated toward differentiated platforms and clinically de-risked assets; Hyperway’s three Phase I programs position it favorably for continued institutional support.
Market Impact & Outlook
- Capital for Clinical Execution: The B+ proceeds — amount undisclosed — will likely fund advancement of the three Phase I programs and progression of the 7-PCC discovery engine toward further IND filings.
- Platform Optionality: The BBB-penetrant platform creates partnership and out-licensing optionality with global pharma seeking CNS delivery solutions.
- Regional Backing: Participation by Chengdu Sci‑Tech Innovation Investment Group and the Yufu High‑Quality Industry Mother Fund underscores local government-linked capital’s role in sustaining innovative biotech clusters in western China.
- Global Ambition: International academic recognition of its research supports the company’s stated foundation for overseas expansion, potentially including global partnering of pipeline assets.
- Next Steps: Continued Phase I execution and pipeline advancement; specific program names, targets, trial timelines, and round valuation were not disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding Hyperway Pharmaceutical’s Series B+ financing, pipeline development, and platform potential. Early-stage drug development carries substantial objective failure risk; Phase I entry does not guarantee safety, efficacy, or approval. Financing details beyond disclosed investor participation and prior-round amounts are unavailable, and actual use of proceeds, timelines, and outcomes may differ from expectations.-Fineline Info & Tech
